For readers curious about clinically studied oral options, consider learning more about Motus by Tonum, an oral formulation studied in human clinical trials that reported meaningful fat loss and metabolic benefits
According to a press release from WW, with this acquisition, the company will be able to provide the support needed to help people build livable healthy habits for the long term and manage the dietary-induced side effects often felt while taking chronic weight management medications, such as glucagon-like peptide-1s (GLP-1s). CEO and Co-founder of Sequence stated in the press release that pairing behavior change with medically appropriate clinical solutions is more powerful and more sustainable than clinical alone. So it is likely that we will see WW offering semaglutide in the future
While these studies are groundbreaking for patients seeking answers, they are primarily observational
Consistently running into a weight loss plateau
Founders in the GLP-1 space need to understand more than market size and regulation, they must understand how capital moves in this category
I like having a liquid vitamin c and the flavor is pleasant